Evidence map›Paper›PMID 32442086›Full record

ReviewCurrent neuropharmacology2020

Transcriptional Factors and Protein Biomarkers as Target Therapeutics in Traumatic Spinal Cord and Brain Injury.

Suneel Kumar, Zachary Fritz, Kunjbihari Sulakhiya, Thomas Theis, Francois Berthiaume

Open access · greenAbstract readReview
In one paragraph

Review in Current neuropharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Clinical applications of stem cell-derived exosomes.Signal transduction and targeted therapy · 2024
    Review
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Suneel KumarDepartment of Biomedical Engineering, The State University of New Jersey, Piscataway, New Jersey, USA
Zachary FritzDepartment of Biomedical Engineering, The State University of New Jersey, Piscataway, New Jersey, USA
Kunjbihari SulakhiyaDepartment of Pharmacy, Indira Gandhi National Tribal University (IGNTU), Amarkantak, India
Thomas TheisW. M. Keck Center for Collaborative Neuroscience and Department of Cell Biology and Neuroscience, Rutgers, The State University of New Jersey, Piscataway, New Jersey, USA
Francois BerthiaumeDepartment of Biomedical Engineering, The State University of New Jersey, Piscataway, New Jersey, USA
Rutgers, The State University of New Jersey · USIndira Gandhi National Tribal University · IN

Funding

UMDNJ TRAINING GRANT IN BIOTECHNOLOGYT32GM008339 · NIGMS · RUTGERS THE ST UNIV OF NJ NEW BRUNSWICK · PI YARMUSH, MARTIN L · 1989 to 2019
$6.1M
NIGMS NIH HHS T32 GM008339
6 · The paper itself

Abstract

Traumatic injury to the spinal cord (SCI) and brain (TBI) are serious health problems and affect many people every year throughout the world. These devastating injuries are affecting not only patients but also their families socially as well as financially. SCI and TBI lead to neurological dysfunction besides continuous inflammation, ischemia, and necrosis followed by progressive neurodegeneration. There are well-established changes in several other processes such as gene expression as well as protein levels that are the important key factors to control the progression of these diseases. We are not yet able to collect enough knowledge on the underlying mechanisms leading to the altered gene expression profiles and protein levels in SCI and TBI. Cell loss is hastened by the induction or imbalance of pro- or anti-inflammatory expression profiles and transcription factors for cell survival after or during trauma. There is a sequence of events of dysregulation of these factors from early to late stages of trauma that opens a therapeutic window for new interventions to prevent/ restrict the progression of these diseases. There has been increasing interest in the modulation of these factors for improving the patient's quality of life by targeting both SCI and TBI. Here, we review some of the recent transcriptional factors and protein biomarkers that have been developed and discovered in the last decade in the context of targeted therapeutics for SCI and TBI patients.

Indexed as

AnimalsBiomarkersBrainBrain InjuriesHumansSpinal Cord InjuriesTranscription FactorsBiomarkersTranscription Factorsbiofluidbiomarkersbrain injuryinflammationregenerationrepairspinal cord injuryTranscription factors

Identifiers

PMID32442086
PMCPMC7709155
OpenAlexW3026177505

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.